RxDoctor Payments Data

Emily Dvorak, NP

Adult Health · Ithaca, NYNPI 1700448503

Payments from drug & device makers

$2,051in general payments, 2019–2025

Across 60 payments — averaging $34.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$988
  • Takeda Pharmaceuticals U.S.A., Inc.$294
  • Johnson & Johnson$201
  • Madrigal Pharmaceuticals$102
  • Braintree Laboratories, Inc.$97
  • Regeneron Healthcare Solutions, Inc.$77
  • plus $292 from 9 others

What the payments were for

  • Food & beverage$2,051100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,051 in reported general payments places this provider in the 80th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$39,655
Medicare patients
229
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide72$71,196
XifaxanRifaximin13$29,392
Lubiprostone76$21,114
Esomeprazole Magnesium131$10,035
ClenpiqSod Picosulf/Mag Ox/Citric Ac32$5,452
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates47$2,774
Omeprazole206$2,543
Rabeprazole Sodium13$2,310
Famotidine96$937
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl68$804
Pantoprazole Sodium53$761
Colestipol Hcl12$695
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$462
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl29$322
Ondansetron OdtOndansetron29$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$988$71,19672 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$33$29,39213 claims
Ferring Pharmaceuticals Inc.Clenpiq$67$5,45232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,828 adult health providers in New York.

Other adult health in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →